...
首页> 外文期刊>European journal of nuclear medicine >Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in patients with chronic coronary artery disease and left ventricular dysfunction: comparison between baseline and nitrate-enhanced imaging
【24h】

Technetium-99m sestamibi imaging to predict left ventricular ejection fraction outcome after revascularisation in patients with chronic coronary artery disease and left ventricular dysfunction: comparison between baseline and nitrate-enhanced imaging

机译:net-99m sestamibi成像可预测慢性冠状动脉疾病和左心功能不全患者血运重建后左心室射血分数的结果:基线和硝酸盐增强成像的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Acceptance of technetium-99m sestamibi as a tracer of myocardial viability is growing, particularly when nitrate-enhanced imaging is used. However, few data are available on the ability of 99mTc-sestamibi to predict the evolution of global left ventricular ejection fraction (EF). The aim of this study was to examine the ability of resting and nitrate 99mTc-sestamibi single-photon emission tomography (SPET) to predict EF changes after revascularisation in patients who have chronic coronary artery disease with left ventricular dysfunction. Using baseline resting and nitrate 99mTc-sestamibi SPET, we studied 61 patients scheduled for revascularisation because of left ventricular dysfunction. EF was estimated using two-dimensional echocardiography before and after the intervention. A post-revascularisation improvement of > or =5 EF units was defined as significant. Using a 13-segment model, 99mTc-sestamibi activity was quantified and the nitrate-induced activity changes calculated. Three different criteria for detecting viability (defined as post-revascularisation reversible dysfunction) in asynergic segments were compared: (1) resting 99mTc-sestamibi activity > or =60%; (2) nitrate 99mTc-sestamibi activity > or =65%; and (3) nitrate-induced increase >+10% or nitrate-induced increase < or =+10% and nitrate activity > or =65%. EF increased significantly in 32 patients. The number of viable asynergic segments was significantly higher in these patients than in the remaining 29 subjects, and the difference was greater (P<0.0002) using definition (3) than using either baseline (P<0.002) or nitrate activity (P<0.0005). There was a significant relationship between EF changes and number of viable asynergic segments: Spearman R=0.38, P<0.005 using baseline; Spearman R=0.39, P<0.002 using nitrate activity; and Spearman R=0.55, P<0.000005 using definition (3). According to receiver operating characteristic (ROC) curve analysis, this last criterion achieved the best results (81% sensitivity, 69% specificity and 75% accuracy), with an area under the ROC curve of 0.838; this area was significantly larger than when using either baseline (0.744, P<0.02) or nitrate activity (0.747, P<0.005). 99mTc-sestamibi SPET appears able to predict the evolution of global left ventricular EF after revascularisation, thereby confirming the value of 99mTc-sestamibi as a tracer of myocardial viability. The combination of baseline resting and nitrate imaging seems to significantly improve the diagnostic accuracy of 99mTc-sestamibi SPET for this particular purpose.
机译:m 99m的西他米作为心肌活力的示踪剂的接受度正在增加,尤其是在使用硝酸盐增强成像的情况下。但是,关于99mTc-司他米比预测整体左心室射血分数(EF)的能力的数据很少。这项研究的目的是检查患有慢性左心功能不全的慢性冠状动脉疾病患者的静息和硝酸盐99mTc-sestamibi单光子发射断层扫描(SPET)预测血运重建后EF改变的能力。使用基线静息和硝酸盐99mTc-Sestamibi SPET,我们研究了61位因左心功能不全而计划进行血运重建的患者。在介入前后,使用二维超声心动图估计EF。血运重建后> 5或= 5 EF单位的改善定义为显着。使用13段模型,对99mTc-司他米比活性进行了定量,并计算了硝酸盐诱导的活性变化。比较了检测非典型性段生存力的三种不同标准(定义为血运重建后可逆功能障碍):(1)静息99mTc-司他他比活性≥60%; (2)硝酸盐99mTc-司他米比活性>或= 65%; (3)硝酸盐诱导的增加≥10%或硝酸盐诱导的增加≥10%且硝酸盐活性≥65%。 EF在32例患者中明显增加。这些患者中可行的非能动性节段数明显高于其余29名受试者,使用定义(3)的差异大于使用基线(P <0.002)或硝酸盐活性(P <0.0005)的差异(P <0.0002) )。 EF的变化与可行的无节段数之间存在显着的关系:Spearman R = 0.38,使用基线P <0.005;使用硝酸盐活性,Spearman R = 0.39,P <0.002;使用定义(3),Spearman R = 0.55,P <0.000005。根据接收器工作特性(ROC)曲线分析,该最后一个标准获得了最佳结果(灵敏度81%,特异性69%和准确度75%),ROC曲线下的面积为0.838;该面积明显大于使用基线(0.744,P <0.02)或硝酸盐活性(0.747,P <0.005)时的面积。 99mTc-sestamibi SPET似乎能够预测血运重建后整体左心室EF的演变,从而证实了99mTc-sestamibi作为心肌活力示踪剂的价值。基线静息和硝酸盐成像相结合似乎可以显着提高针对该特定目的的99mTc-西他米比SPET的诊断准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号